Rett syndrome: Neurobiological changes underlying specific symptoms

Progress in Neurobiology

Volumn 51, Issue 4, 1997, Pages 383-391

  Wenk, Gary L ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOCHONDRIAL DNA;

CHOLINERGIC SYSTEM; DEMENTIA; DOPAMINERGIC SYSTEM; ENERGY METABOLISM; FEMALE; FOREBRAIN; HISTOLOGY; HUMAN; MALE; MESENCEPHALON; PRIORITY JOURNAL; RETT SYNDROME; REVIEW;

EID: 0031104781     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-0082(96)00059-7     Document Type: Article

References (91)

1. Åkesson H.-O., Hagberg B., Wahlström J., Witt-Engerström I. Rett syndrome: search for gene sources. Am. J. Med. Genet. 42:1992;104-110.
2. Anvret M., Wahlström J. Rett syndrome: random X chromosome inactivation. Clin. Genet. 45:1994;274-275.
3. Anvret M., Wahlström J., Skogsberg P., Hagberg B. Segregation analysis of the X chromosome in a family with Rett syndrome in two generations. Am. J. Med. Genet. 37:1990;31-35.
4. Anvret M., Zhang Z.P. Current status of genetic research in Rett syndrome. Neuropediatrics. 26:1995;88-89.
5. Anvret M., Zhang Z.P., Hagberg B. Rett syndrome: the bcl-2 gene - a mediator of neurotrophic mechanism? Neuropediatrics. 25:1994;323-324.
6. Armstrong D. The neuropathology of Rett syndrome. Brain Dev. 14:1992;589-594.
7. Armstrong D.D. The neuropathology of Rett syndrome - overview 1994. Neuropediatrics. 26:1995;100-104.
8. Bauman M.L., Kemper T.L., Arin D.M. Microscopic observations of the brain in Rett syndrome. Neuropediatrics. 26:1995;105-108.
9. Belichenko P.V., Dahlström A. Confocal laser scanning microscopy and 3D reconstructions of neuronal structures in human brain cortex. Neuroimage. 2:1995;201-207.
10. Belichenko P.V., Oldfors A., Hagberg B., Dahlström A. Rett syndrome: 3D confocal microscopy of cortical pyramidal dendrites and afferents. NeuroReport. 5:1994;1509-1513.
11. Brase D.A., Myer E.C., Dewey W.L. Minireview: possible hyperendorphinergic pathophysiology of the Rett syndrome. Life Sci. 45:1989;359-366.
12. Brucke T., Sofic E., Killian W., Rett A., Riederer P. Reduced concentrations and increased metabolism of biogenic amines in a single case of Rett syndrome: a post mortem brain study. J. Neural. Trans. 68:1987;315-329.
13. Budden S.S., Myer E.C., Butler I.J. Cerebrospinal fluid studies in the Rett syndrome: biogenic amines and beta-endorphins. Brain Dev. 12:1990;81-84.
14. Chiron C., Bultreau C., Loc'h C., Raynaud C., Garreau B., Syrota A., Maziere B. Dopaminergic D2 receptor SPECT imaging in Rett syndrome: increase of specific binding in striatum. J. Nucl. Med. 34:1993;1717-1721.
15. Coker S.B., Melnyk A.R. Rett syndrome and mitochondrial enzyme deficiencies. J. Child. Neurol. 6:1991;164-166.
16. Commings D.E. The genetics of Rett syndrome: the consequences of a disorder where every case is a new mutation. Am. J. Med. Genet. 24:1986;383-388.
17. Cornford M.E., Philippart M., Jacobs B., Scheibel A.B., Vinters H.V. Neuropathology of Rett syndrome: case report with neuronal and mitochondrial abnormalities in the brain. J. Child Neurol. 9:1994;424-431.
18. Doti M.T., Manneschi L., Malandrini A., De Stefano N., Caznerale F.et al. Mitochondrial dysfunction in Rett syndrome: an ultrastructural and biochemical study. Brain Dev. 15:1993;103-106.
19. Eeg-Olofsson O., Al-Zuhair A.G., Teebi A.S., Al-Essa M.M. Abnormal mitochondria in the Rett syndrome. Brain Dev. 10:1988;260-262.
20. Genazzani A.R., Zapella M., Nalin A., Hayek Y., Facchinetti F. Reduced cerebrospinal fluid β-endorphin levels in Rett syndrome. Child Nerv. Syst. 5:1989;111-113.
21. Gao X.M., Fukamauchi F., Chuang D.M. Long-term biphasic effects of lithium treatment on phospholipase C-coupled M3-muscarinic acetylcholine receptors in cultured cerebellar granule cells. Neurochem. Intl. 22:1993;395-403.
22. Gibbs R.B. Expression of estrogen receptor-like immunoreactivity by different subgroups of basal forebrain cholinergic neurons in gonadectomized male and female rats. Brain Res. 720:1996;61-68.
23. Haas, R.H., Light, M., Rice, M. and Barshop, B.A. (1995a) Oxidative metabolism in Rett syndrome: 1. Clinical studies. Neuropediatrics 26, 90-94.
24. Haas R.H., Love S. Peripheral nerve findings in Rett syndrome. J. Child Neurol. 3:1988;S25-S30.
25. Haas, R.H., Nasirian, F., Hua, X., Nakano, K. and Hennessy, M. (1995b) Oxidative metabolism in Rett syndrome: 2. Biochemical and molecular studies. Neuropediatrics 26, 95-99.
26. Haas R.H., Nasirian F., Nakano K., Cepin M., Rajalingam R. Muscle and fibroblast mitochondrial studies in Rett syndrome (abstract). Ann. Neurol. 34:1993;484.
27. Haas R.H., Rice M.A. Is Rett's syndrome a disorder of carbohydrate metabolism? Hyperpyruvicemia and treatment by ketogenic diet (abstract). Ann. Neurol. 18:1985;418.
28. Hagberg B., Aicardi J., Dias K., Ramos O. A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett syndrome: report of 35 cases. Ann. Neurol. 14:1983;471-479.
29. Hagberg B., Goutieres F., Hanefeld F., Rett A., Wilson J. Rett syndrome: criteria for inclusion and exclusion. Brain Dev. 7:1985;372-373.
30. Hagberg B., Skjedal O.H. Rett variants: a suggested model for inclusion criteria. Pediatr. Neurol. 11:1994;5-11.
31. Hagberg B., Witt-Engerström I. Rett syndrome: a suggested staging system for describing impairment profile with increasing age towards adolescence. Am. J. Med. Gen. 24:1986;47-59.
32. Hamberger A., Gillberg C., Palm A., Hagberg B. Elevated CSF glutamate in Rett syndrome. Neuropediatrics. 23:1992;212-213.
33. Hanefeld F., Christen H.-J., Holzbach U., Kruse B., Frahm J., Hänicke W. Cerebral proton magnetic resonance spectroscopy in Rett syndrome. Neuropediatrics. 26:1995;126-127.
34. Hefti F. Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transsections. J. Neurosci. 6:1986;2155-2162.
35. +/K + -ATPase activity in long-term stimulation of nicotinic acetylcholine receptors in C2C12 myotubes. Br. J. Pharmacol. 111:1994;459-464.
36. Holm V.A. Physical growth and development in patients with Rett syndrome. Am. J. Med. Genet. 24:1986;119-126.
37. Hu Z., Yuri K., Ichikawa T., Kawata M. Exposure of postnatal rats to glucocorticoids suppresses the development of choline acetyltransferase-immunoreactive neurons: role of adrenal steroids in the development of forebrain cholinergic neurons. J. Chem. Neuroanat. 10:1996;1-10.
38. Huttenlocher P.R. Synaptic density in human frontal cortex - developmental changes and effect of aging. Brain Res. 163:1979;195-205.
39. Jellinger K., Armstrong D., Zoghbi H.Y., Percy A.K. Neuropathology of Rett syndrome. Acta Neuropathol. 76:1988;142-158.
40. Jellinger K., Seitelberger F. Neuropathology of Rett syndrome. Am. J. Med. Genet. 24:1986;259-288.
41. Kentroti S., Vernadakis A. Ethanol neurotoxicity in culture: selective loss of cholinergic neurons. J. Neurosci. Res. 44:1996;577-585.
42. 3H]Vesamicol binding in human brain cholinergic deficiency disorders. Neurosci. Lett. 117:1990;347-352.
43. Kish S., Karlinsky H., Becker L., Gilbert J., Rebbetoy M., Chang L.-J., DiStefano L., Hornykiewicz O. Down's syndrome individuals begin life with normal levels of brain cholinergic markers. J. Neurochem. 52:1989;1183-1187.
44. Kitt C.A., Troncoso J.C., Price D.L., Naidu S., Moser H.W. Topological changes in substantia nigra and basal forebrain neurons in Rett syndrome. Ann. Neurol. 28:1990;416-417.
45. Kitt C.A., Wilcox B.J. Preliminary evidence for neurodegenerative changes in the substantia nigra of Rett syndrome. Neuropediatrics. 26:1995;114-118.
46. Lappalainen R., Lindholm D., Riikonen R. Low levels of nerve growth factor in cerebrospinal fluid of children with Rett syndrome. J. Child Neurol. 11:1996;296-300.
47. Lekman A., Witt-Engerström I., Gottfries J., Hagberg B., Percy A.K., Svennerholm L. Rett syndrome: biogenic amines and metabolites in postmortem brain. Pediatr. Neurol. 5:1989;357-362.
48. Lekman A., Witt-Engerström I., Holmberg B., Percy A., Svennerholm L., Hagberg B. CSF and urine biogenic amine metabolites in Rett syndrome. Clin. Genet. 37:1990;173-178.
49. Luine V.N. Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. Expl Neurol. 89:1985;484-490.
50. Matsuishi T., Urabe F., Komori H., Yamashita Y., Naito E.et al. The Rett syndrome and CSF lactate acid patterns. Brain Dev. 14:1992;68-70.
51. Matsuishi T., Urabe F., Percy A.K., Komori H., Yamashita Y., Schultz R.S., Ohtani Y., Kuriya N., Kato H. Abnormal carbohydrate metabolism in cerebrospinal fluid in Rett syndrome. J. Child Neurol. 9:1994;26-30.
52. Mesulam M.-M., Mufson E.J., Wainer B.H., Levey A.I. Central cholinergic pathways in the rat: an overview on an alternative nomenclature. Neurosci. 10:1983;1185-1201.
53. Meyer E.C., Tripathi H.L., Brase D.A., Dewey W.L. Elevated CSF beta-endorphin immunoreactivity in Rett's syndrome: report of 158 cases and comparison with leukemic children. Neurology. 42:1992;357-360.
54. Migeon B.R., Dunn M.A., Thomas G., Schmeckpepper B.J., Naidu S. Studies of X inactivation and isodisomy in twins provide further evidence that the X chromosome is not involved in Rett syndrome. Am. J. Hum. Genet. 56:1995;647-653.
55. Mobley W.C., Rutkowski J.L., Tennekoon G.I., Gemski J., Buchanan K., Johnston M.V. Nerve growth factor increases choline acetyltransferase activity in developing basal forebrain neurons. Molec. Brain Res. 1:1986;53-62.
56. Motil K.J., Schultz R., Brown B., Glaze D.G., Percy A.K. Altered energy balance may account for growth failure in Rett syndrome. J. Child Neurol. 9:1994;315-319.
57. Naidu S., Hyman S., Harris E.L., Narayanan V., Johns D., Castora F. Rett syndrome studies of natural history and search for a genetic marker. Neuropediatrics. 26:1995;63-66.
58. Naidu S., Wong D.F., Kitt C.A., Wenk G.L., Moser H.W. Positron emission tomography in the Rett syndrome: clinical, biochemical and pathological correlates. Brain Dev. 14:1992;S75-S79.
59. Nielsen, J.B., Bertelsen, A. and Lou, H.C. (1992) Low CSF HVA levels in the Rett syndrome: a reflection of restricted synapse formation?. Brain Dev. 14, S63-65.
60. Nielsen J.B., Toft P.B., Reske-Nielsen E., Jensen K.E., Christiansen P.et al. Cerebral magnetic resonance spectroscopy in Rett syndrome. Failure to detect mitochondrial disorder. Brain Dev. 15:1993;107-112.
61. Nomura Y., Segawa M., Higurashi M. Rett syndrome and early catecholamine and indolamine deficient disorder. Brain Dev. (Tokyo). 7:1985;334-341.
62. Oldfors A., Sourander P., Armstrong D.L., Percy A.K., Witt-Engerström I., Hagberg B.A. Rett syndrome: cerebellar pathology. Pediatr. Neurol. 6:1990;310-314.
63. Pedata F., Lo Conte G., Sorbi S., Marconcini-Pepeu I., Pepeu G. Changes in high affinity choline uptake in rat cortex following lesions of the magnocellular forebrain nuclei. Brain Res. 233:1982;359-367.
64. Percy A.K., Glaze D.G., Schultz R.J., Zoghbi H.Y., Williamson D., Frost J.D. Jr., Jankovic J.J., del Junco D., Skender M., Waring S., Myer E.C. Rett syndrome: controlled study of an oral opiate antagonist, naltrexone. Ann. Neurol. 35:1994;464-470.
65. Perry T.L., Dunn H.G., Ho H.H., Crichton J.U. Cerebrospinal fluid values for monoamine metabolites, γ-aminobutyric acid, and other amino compounds in Rett syndrome. J. Pediatr. 112:1988;234-238.
66. Philipart M., Brown W.J. Dystonia and lactic acidosis: new features of Rett's syndrome (abstract). Ann. Neurol. 16:1984;387.
67. Plioplys A.V., Kasnicka I. L-Carnitine as a treatment for Rett syndrome. Sci. Med. J. 86:1993;1411-1412.
68. Reiss A.L., Faruque F., Naidu S., Abrams M., Beaty T., Bryan R.N. Neuroanatomy of Rett syndrome: a volumetric imaging study. Ann. Neurol. 34:1993;227-334.
69. Rett Syndrome Diagnostic Criteria Work Group Diagnostic criteria for Rett syndrome. Ann. Neurol. 23:1988;425-428.
70. Rett A. Uber ein zerebral-atrophisches syndrom bei hyperammonamie. Wein Med. Wschr. 116:1966;723-726.
71. Riederer P., Brucke T., Sofic E., Kienzl E., Schnecker K., Schay V., Kruzik P. Neurochemical aspects of the Rett syndrome. Brain Dev. 7:1985;351-360.
72. Riederer P., Weiser M., Wichart I., Schmidt B., Killian W., Rett A. Preliminary brain autopsy findings in progredient Rett syndrome. Am. J. Med. Genet. 24:1986;305-315.
73. 3H]vesamicol binding in the temporal cortex of patients with Alzheimer's disease, Parkinson's disease, and rats with basal forebrain lesions. Neuroscience. 35:1990;327-333.
74. Ruch A., Kurczynski T.W., Velasco M.E. Mitochondrial alterations in Rett syndrome. Pediatr. Neurol. 5:1989;320-323.
75. Schultz P., Glaze D.G., Motil K.J., Armstrong D., del Junco D., Hubbard H.J.et al. The pattern of growth failure in Rett syndrome. Am. J. Dis. Child. 147:1993;633-637.
76. Skjeldal O.H., Nicolaysen R.B., Lindal S., Skullerud K., Bostad R.et al. Rett syndrome: biochemical investigations on muscle tissue in a girl with abnormal mitochondria. J. Child Neurol. 8:1993;101.
77. Stenbom Y., Witt Engerström I., Hagberg G. Gross motor disability and head growth in Rett syndrome - A preliminary report. Neuropediatrics. 26:1995;85-86.
78. Steriade, M. and Buzsaki, G. (1990) Parallel activation of thalamic and cortical neurons by brainstem and basal forebrain cholinergic systems. In: Brain cholinergic systems, pp. 3-62. Steriade, M. and Biesold, D. (Eds.), Oxford University Press, Oxford.
79. Trevathan E., Moser H.V. Diagnostic criteria for Rett syndrome. Ann. Neurol. 23:1988;425-428.
80. Wakai S., Kameda K., Ishikawa Y., Miyamoto S., Nagaoka M., Okabe M., Minami R., Tachi N. Rett syndrome: findings suggesting axonopathy and mitochondrial abnormalities. Pediatr. Neurol. 6:1990;339-343.
81. Wenk G.L. Alterations in dopaminergic function in Rett syndrome. Neuropediatrics. 26:1995;123-123.
82. Wenk G.L., Mobley S.L. Choline acetyltransferase activity and vesamicol binding in Rett Syndrome and in rats with nucleus basalis lesions. Neurosci. 73:1996;79-84.
83. 3H)-choline uptake into acetylcholinergic neurons of the nucleus basalis magnocellularis and the medial septal area. Behav. Brain Res. 13:1984;129-138.
84. Wenk G.L., Naidu S., Casanova M.F., Kitt C.A., Moser H. Altered neurochemical markers in Rett syndrome. Neurology. 41:1991;1753-1756.
85. Wenk G.L., O'Leary M., Nemeroff C.B., Bissette G., Moser H., Naidu S. Neurochemical alterations in Rett syndrome. Develop. Brain Res. 74:1993;67-72.
86. Wenk H., Bigl V., Meyer U. Cholinergic projections from magnocellular nuclei of the basal forebrain to cortical areas in rats. Brain Res. Rev. 2:1980;295-316.
87. Whitehouse P.J., Price D.L., Clark A.W., Coyle J.T., DeLong M.R. Alzheimer's disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol. 10:1981;122-126.
88. Zappella M., Genazzani A. Girls with Rett syndrome treated with bromocriptine. Wien. Klin. Wochenschr. 98:1986;22.
89. Zoghbi H.Y., Ledbetter D.H., Schultz R.J., Percy A.K., Glaze D.G. A de novo X: 3 translocation in Rett syndrome. Am. J. Med. Genet. 35:1990;148-151.
90. Zoghbi H.Y., Percy A.K., Glaze D.G., Butler I.J., Riccardi V.M. Reduction of biogenic amine levels in the Rett syndrome. N. Engl. J. Med. 313:1985;921-924.
91. Zoghbi H.Y., Sheldon M., Butler I.J., O'Brian Smith E., Kaufman S., Glaze D.G., Percy A.K. Cerebrospinal fluid biogenic amines and biopterin in Rett syndrome. Ann. Neurol. 25:1989;56-60.